Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
2023;24(1):e13325
Indeed, deficiency in ribose-5-phopshate isomerase is considered to be second rarest disorder world-wide
In preclinical models, it has demonstrated pro-angiogenic, cytoprotective, and anti-inflammatory properties 1-3
All these trials were designed to evaluate the primary outcome of 3-MACE defined as cardiovascular death, nonfatal myocardial infarct, and nonfatal stroke, except for the ELIXA trial of exenatide ER, which included hospitalization for unstable angina as an additional component of the 4-MACE composite outcomes
US$ 19.99
US$ 24.87
US$ 28.86
US$ 25.06
